APA

Steudel W., Dingmann C., Zhang Y., Bendrick-Peart J., Clavijo C., Shulze J., Betts R. & Christians U. (20110323). Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals. : Journal of clinical pharmacology.

Chicago

Steudel Wolfgang, Dingmann Colleen, Zhang Yan-Ling, Bendrick-Peart Jamie, Clavijo Claudia, Shulze John, Betts Ronald and Christians Uwe. 20110323. Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals. : Journal of clinical pharmacology.

Harvard

Steudel W., Dingmann C., Zhang Y., Bendrick-Peart J., Clavijo C., Shulze J., Betts R. and Christians U. (20110323). Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals. : Journal of clinical pharmacology.

MLA

Steudel Wolfgang, Dingmann Colleen, Zhang Yan-Ling, Bendrick-Peart Jamie, Clavijo Claudia, Shulze John, Betts Ronald and Christians Uwe. Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals. : Journal of clinical pharmacology. 20110323.